Sanofi: Influenza, Human trials

The registry lists 139 Influenza, Human studies with Sanofi as lead sponsor. 4 are open to participants now and 73 have results posted.

Phase 1 24Phase 2 47Phase 3 35Phase 4 33No phase 13(a study in two phases counts in both)

Studies

Page 1 of 2. Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Study of a Combination SARS-CoV-2 Recombinant Spike and High-Dose Inactivated Influenza Vaccine With Matrix-M Adjuvant in Adult Participants 60 Years of Age and OlderRecruitingNCT07890454Phase 3
• Study to Assess Safety and Immunogenicity of an Egg-based H5N8 Influenza Vaccine at Multiple Dose Levels Adjuvanted With Matrix-M in Healthy Participants 18 Years of Age and Above.RecruitingNCT07779408Phase 1/2
• Post-marketing Surveillance Study for the Safety of Efluelda® Pre-filled SyringeRecruitingNCT07282795
• Post-marketing Surveillance Study for the Safety of Efluelda Tetra Pre-filled Syringe.Not yet recruitingNCT06694025
• A Study to Investigate the Safety and Immunogenicity of the Quadrivalent Influenza mRNA Vaccines in Adults Aged 18 Years and AboveCompletedNCT06361875Phase 1/2Results posted
• Study on Two Adjuvanted Dose Levels of Panblok H7+MF59 Compared for Immunogenicity and Safety With an Unadjuvanted Dose of Panblok H7 in Participants 18 Years of Age and OlderCompletedNCT05608005Phase 1/2Results posted
• Study With Quadrivalent Recombinant Influenza Vaccine (RIV4) Compared With Egg-Based Quadrivalent Influenza Vaccine (IIV4) in Participants Aged 3 to 8 YearsTerminatedNCT05513391Phase 3Results posted
• Study With Quadrivalent Recombinant Influenza Vaccine (RIV4) in Participants 9 Through 49 Years of Age.CompletedNCT05513053Phase 3Results posted
• Study Describing the Immunogenicity and Safety of Quadrivalent Recombinant Influenza Vaccine (RIV4) Versus a Licensed Quadrivalent-inactivated Influenza Vaccine (IIV4) (Fluarix® Quadrivalent) in Participants 18 Years of Age and Older in South KoreaCompletedNCT05144945Phase 3Results posted
• Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2021-2022 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, RespectivelyCompletedNCT05050318Phase 4Results posted
• Study of a Quadrivalent High-Dose Influenza Vaccine and a Moderna COVID-19 Vaccine Administered Either Concomitantly or Singly in Participants 65 Years of Age and Older Previously Vaccinated With a 2-dose Schedule of Moderna COVID-19 VaccineCompletedNCT04969276Phase 2Results posted
• Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2020-2021 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, RespectivelyCompletedNCT04551677Phase 4Results posted
• Study on a High-Dose Quadrivalent Influenza Vaccine Compared With Standard-Dose Quadrivalent Influenza Vaccine in Children 6 Months Through 35 Months of AgeTerminatedNCT04544267Phase 3Results posted
• Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Taiwanese Adults 65 Years of Age and OlderCompletedNCT04537234Phase 3Results posted
• Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Japanese Adults 60 Years of Age and OlderCompletedNCT04498832Phase 3Results posted
• Study to Evaluate the Effectiveness of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Adults 65 Years of Age and OlderTerminatedNCT04137887Phase 3Results posted
• Collection of Serum Samples From Children and Older Adults Receiving the 2019-2020 Formulations of Fluzone® Quadrivalent and Fluzone® High-Dose Influenza Vaccines, RespectivelyCompletedNCT04109222Phase 4Results posted
• Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Europeans Adults 60 Years of Age and OlderCompletedNCT04024228Phase 3Results posted
• Safety and Immunogenicity of Different Dosages of High-Dose Quadrivalent Influenza Vaccine in Children 6 Months to 17 Years of AgeCompletedNCT03698279Phase 2Results posted
• Safety and Immunogenicity of Fluzone® Quadrivalent, Flublok® Quadrivalent, and Fluzone® High-Dose, Influenza Vaccines, 2018-2019 FormulationsCompletedNCT03617523Phase 4Results posted
• Immunogenicity and Safety of Fluzone® Quadrivalent, Southern Hemisphere 2015 Formulation (Intramuscular Route)CompletedNCT03546192Phase 4Results posted
• Safety and Immunogenicity of Fluzone® Quadrivalent and Fluzone® High-Dose, Influenza VaccinesCompletedNCT03308825Phase 4Results posted
• Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Participants ≥65 Years in the USCompletedNCT03282240Phase 3Results posted
• Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Patients ≥65 YearsCompletedNCT03233217Phase 1/2Results posted
• Safety and Immunogenicity of Fluzone® Quadrivalent Vaccine Administered to Healthy ChildrenCompletedNCT02915302Phase 4Results posted
• Safety and Immunogenicity of Fluzone® Quadrivalent and Fluzone® High-Dose, Influenza Vaccines, 2016-2017 FormulationsCompletedNCT02908269Phase 4Results posted
• Study of Fluzone® Quadrivalent, Fluzone® Intradermal Quadrivalent, and Fluzone® High-Dose, Influenza Vaccines in AdultsCompletedNCT02563093Phase 4Results posted
• Immunogenicity and Safety of a Quadrivalent Influenza Vaccine Given by Intramuscular Route in Subjects Aged 18 to 60 YearsCompletedNCT02550197Phase 3Results posted
• Safety and Immunogenicity of the 2015-2016 Formulation of Fluzone® Quadrivalent (Influenza Vaccine) Among Healthy ChildrenCompletedNCT02539108Phase 4Results posted
• Study of a Single Dose or Two Doses of a Quadrivalent Influenza Vaccine in Subjects Aged 6 Months or Older in IndiaCompletedNCT02451358Phase 3Results posted
• Study of Fluzone® Quadrivalent, Fluzone® Intradermal, and Fluzone® High-Dose, Influenza Vaccines in AdultsCompletedNCT02258334Phase 4Results posted
• Study of a Single Dose or Two Doses of a Trivalent Inactivated Influenza Vaccine Produced at Shenzhen, ChinaCompletedNCT02228980Phase 4Results posted
• Safety and Immunogenicity Among Healthy Children Receiving Fluzone® Quadrivalent, Influenza VaccineCompletedNCT02222870Phase 4Results posted
• Study of a Quadrivalent Influenza Vaccine Administered Via the Intramuscular Route in Children and Adolescents in TaiwanCompletedNCT01967784Phase 3Results posted
• Study of Fluzone® Quadrivalent, Fluzone® Intradermal, and Fluzone® High-Dose Influenza Virus Vaccines in AdultsCompletedNCT01946438Phase 4Results posted
• Safety and Immunogenicity Among Healthy Children Receiving Fluzone® Quadrivalent Influenza Virus VaccineCompletedNCT01946425Phase 4Results posted
• Study of Intradermal Quadrivalent Influenza Vaccine in Adults Aged 18 Through 64 YearsCompletedNCT01712984Phase 3Results posted
• Study of Fluzone® Influenza Virus Vaccines 2012-2013 Formulation Among Adults.CompletedNCT01691339Phase 4Results posted
• Safety and Immunogenicity Among Healthy Children Receiving Fluzone® Influenza Virus Vaccine (2012-2013 Formulation)CompletedNCT01691326Phase 4Results posted
• Study of Fluzone® Influenza Virus Vaccine 2011-2012 Formulation (Intramuscular Route) Among AdultsCompletedNCT01430819Phase 4Results posted
• A Study of Fluzone® High-Dose Vaccine Compared With Fluzone® Vaccine In Elderly AdultsCompletedNCT01427309Phase 4Results posted
• A Study of High-Dose Trivalent Inactivated Influenza Vaccine in Adults 50 to 64 Years of AgeCompletedNCT01258595Phase 2Results posted
• Study of Quadrivalent Influenza Vaccine Among ChildrenCompletedNCT01240746Phase 3Results posted
• Study of Quadrivalent Influenza Vaccine Among AdultsCompletedNCT01218646Phase 3Results posted
• Study of Influenza Vaccine Revaccination in Healthy Adults Previously Vaccinated With Fluzone ID or Fluzone IMCompletedNCT01011049Phase 2Results posted
• A Study of Influenza Virus Vaccines in Children and AdultsCompletedNCT00988143Phase 2Results posted
• Multi-Year Study of Fluzone High-Dose Influenza Vaccine Compared With Fluzone® Vaccine in Adults Aged 65 Years and OlderTerminatedNCT00976027Phase 3Results posted
• A Study of Different Formulations of an A/H1N1 Pandemic Vaccine in Healthy Adults and the ElderlyCompletedNCT00953524Phase 2Results posted
• A Study of Different Formulations of an A/H1N1 Pandemic Vaccine in Healthy Children Aged 6 Months to 9 YearsCompletedNCT00952419Phase 2Results posted
• A Study of Different Formulations of an Adjuvanted A/H1N1 Pandemic Vaccine in Healthy Adults and the ElderlyCompletedNCT00952276Phase 2Results posted
• Evaluation of Responses to Fluzone® in Infants ≥ 6 Months of Age Who Did or Did Not Receive Fluzone® at 2 Months of AgeCompletedNCT00885105Phase 3Results posted
• Safety and Immunogenicity Testing of Influenza Vaccine in Healthy Children 2 Months and 6 Months of AgeCompletedNCT00858468Phase 1/2Results posted
• Immunogenicity of a Split, Cell-Based, Inactivated, Trivalent Influenza Vaccine in Healthy Adult SubjectsCompletedNCT00845429Phase 2Results posted
• Study to Collect Sera for Immunogenicity Testing in Children Vaccinated With Fluzone®CompletedNCT00836953Phase 4Results posted
• A Study to Evaluate the Safety and Immune Responses to Fluzone® VaccinationCompletedNCT00835926Phase 4Results posted
• Safety and Immunogenicity of the World Health Organization (WHO) Formulation of the 2004-2005 Fluzone® VaccineCompletedNCT00831987Phase 4Results posted
• Study of Safety and Immunogenicity of Fluzone® in Healthy ChildrenCompletedNCT00831675Phase 4Results posted
• Safety Study of Recombinant M2e Influenza-A Vaccine in Healthy AdultsCompletedNCT00819013Phase 1Results posted
• Influenza Vaccine Revaccination in Ambulatory Elderly SubjectsCompletedNCT00775450Phase 2Results posted
• Study of Fluzone Vaccine Administered by Intradermal Route in Comparison With Standard Fluzone® in AdultsCompletedNCT00772109Phase 3Results posted
• Annual Study for Serum Collection for Immunogenicity and Safety Evaluation in Healthy Children Receiving Fluzone®CompletedNCT00755274Phase 4Results posted
• A Study to Evaluate the Safety and Immune Responses to Fluzone® VaccinationCompletedNCT00743275Phase 4Results posted
• Study to Determine a Preference for Fluzone Vaccine Given Intradermally (ID) and Intramuscularly (IM) in Healthy AdultsCompletedNCT00623181Phase 2Results posted
• Phase IV Trial to Collect Safety Data and Sera for Immunogenicity Testing in Healthy Children Given Fluzone® VaccineCompletedNCT00561002Phase 4Results posted
• Study of Inactivated, Split-Virion Influenza Vaccine and Standard Fluzone® Vaccine in Adult and Elderly SubjectsCompletedNCT00551031Phase 2Results posted
• Immunogenicity, Safety, Reactogenicity, Efficacy, Effectiveness and Lot Consistency of FluBlokCompletedNCT00539981Phase 3Results posted
• Trial to Describe the Safety and Immunogenicity of Fluzone®CompletedNCT00524940Phase 2Results posted
• Immunogenicity Study of Antibody Persistence and Booster Effect of DTaP-HB PRP~T Combined Vaccine in Filipino InfantsCompletedNCT00514709Phase 3Results posted
• Study of Inactivated, Split-Virion Influenza Vaccine Compared With Standard Fluzone Vaccine in Infants and ChildrenCompletedNCT00391391Phase 2Results posted
• Immunogenicity of High-dose Inactivated, Split-virion Influenza Vaccine Versus Standard Fluzone Vaccine in the ElderlyCompletedNCT00391053Phase 3Results posted
• Safety and Immunogenicity of Fluzone® Vaccine in Children Who Received 2 Doses of the 2005-2006 Fluzone Formulation.CompletedNCT00390884Phase 4Results posted
• Trial to Collect Safety Data and Sera for Immunogenicity TestingCompletedNCT00389857Phase 4Results posted
• Phase IV Trial to Determine the Safety and Immunogenicity of the WHO Formulation of the 2006-2007 Fluzone® VaccineCompletedNCT00389532Phase 4Results posted
• Study of Inactivated, Split-Virion Influenza Vaccine Compared With Standard Fluzone Vaccine in Elderly SubjectsCompletedNCT00388583Phase 2Results posted
• Study Comparing a DTaP-HB-PRP~T Combined Vaccine With Tritanrix HepB/Hib™, Concomitantly With OPV in Healthy InfantsCompletedNCT00348881Phase 3Results posted
• Safety and Immunogenicity of the 2005-2006 Fluzone® VaccineCompletedNCT00258830Phase 4Results posted
• Phase IV Trial to Collect Safety Data and Sera in Healthy Children Given Fluzone VaccineCompletedNCT00258817Phase 4Results posted
• Study of Different Formulations of Vaccines Encoding the RSV Monovalent Antigen or the Flu H5 Antigen in Participants 18 to 49 Years of AgeActive, not recruitingNCT07516418Phase 1
• Study to Evaluate the Safety and the Immunogenicity of a Second Generation Structurally Designed mRNA Vaccine Candidate Against Pandemic Influenza H5 HA Strain in Healthy Adult Participants Aged 18 Years and OlderActive, not recruitingNCT06907511Phase 1/2
• A Study on the Safety and Immunogenicity of Influenza, Respiratory Syncytial Virus, Human Metapneumovirus and Parainfluenza Vaccines in Adults 18 to 49 Years of Age.CompletedNCT06850051Phase 1
• Repeated Cross Sectional Surveillance Study To Determine the Influenza Vaccination Rates in German ParticipantsCompletedNCT06800885
• A Study to Assess Tolerability of the Trivalent Recombinant Vaccine in Individuals Aged 18 and Older Using the Vaccinees Perception of Injection QuestionnaireCompletedNCT06765187
• A Study on the Safety and Immunogenicity of Hexavalent Influenza mRNA Vaccine in Adult Participants 50 Years of Age and OlderCompletedNCT06744205Phase 1/2
• Study to Evaluate Safety and Immunogenicity of a Pandemic Flu H5 mRNA Vaccine in Healthy Adults Aged 18 Years and OlderCompletedNCT06727058Phase 1/2
• Study of a Combination Vaccine Comprised of Different Recombinant Spike Antigen Levels of a Matrix-M Adjuvanted Recombinant COVID-19 Vaccine and Recombinant Influenza Vaccine in Adult Participants 50 Years of Age and OlderCompletedNCT06695130Phase 1/2
• Study of a Combination Vaccine Comprised of Different Recombinant Spike Antigen Levels of a Matrix-M Adjuvanted Recombinant COVID-19 Vaccine and High-Dose Inactivated Influenza Vaccine in Adult Participants 50 Years of Age and OlderCompletedNCT06695117Phase 1/2
• Study to Evaluate Immunogenicity and Safety of a High-Dose Influenza Vaccine in Adults 50 Through 64 Years of AgeCompletedNCT06641180Phase 3
• Study of Influenza Vaccines Containing an Additional H3 Antigen in Healthy Adult Participants 18 to 49 Years of Age and 60 Years of Age and OlderCompletedNCT06507553Phase 1
• Safety and Immunogenicity of a Monovalent mRNA Vaccine Encoding Influenza Hemagglutinin in Adult Participants 18 Years of Age and OlderCompletedNCT06118151Phase 1
• Safety Surveillance of VaxigripTetra® and Efluelda® Influenza Vaccines in Europe During the Influenza Season 2023/24CompletedNCT06059456
• Postmarketing Surveillance Study for Quadrivalent Influenza Vaccine (VaxigripTetra®) in Subjects Aged 6 to 35 MonthsCompletedNCT05832333
• Substudy 01 - Safety and Immunogenicity of One Monovalent Modified mRNA Vaccine Encoding Influenza Hemagglutinin With LNP, in Adult Participants Aged 18 to 49 Years and 60 Years and AboveCompletedNCT05829356Phase 1
• Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5413 in Adult Participants18 Years of Age and OlderCompletedNCT05650554Phase 1/2
• Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5410 in Adult Participants 18 Years of Age and OlderCompletedNCT05624606Phase 1/2
• Safety Surveillance of VaxigripTetra® and Efluelda® Influenza Vaccines in Europe During the Influenza Season 2022/23CompletedNCT05568979
• Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5407 in Adult Participants18 Years of Age and OlderCompletedNCT05553301Phase 1/2
• Study to Assess the Safety and Immunogenicity of Monovalent mRNA NA Vaccine in Adult Participants 18 Years of Age and OlderCompletedNCT05426174Phase 1
• Postmarketing Surveillance Study for Quadrivalent Influenza Vaccine (VaxigripTetra Inj.) in Subjects Aged 3 Years Old and AboveCompletedNCT05406180
• Safety Surveillance of VaxigripTetra® and Efluelda® Influenza Vaccines in Europe During the Influenza Season 2021/22CompletedNCT05078060
• Surveillance Study to Assess the Safety of Flublok Quadrivalent (Influenza Vaccine) in Pregnant Women and Their OffspringCompletedNCT04460781